Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

ALzheimer COoperative Valuation in Europe

The JA will be contribute to public health programmes in Europe and develop Alzheimers disease (AD) and dementia prevention and care models in different European countries. The aim is to contribute to improvements in health by supporting and facilitating quality and efficiency of public health and healthcare policies and interventions. Synergy and...
Funding Programme
Start Date
End Date
Total Funding
€ 613 100

Alzheimer’s disease data-driven insights on individual outcomes of importance

ADDITION

Alzheimer’s disease (AD) is the most common cause of dementia in the elderly, and a major reason for disability and death. The time course of AD varies between different people affected, and being able to tell in advance how the disease is likely to progress would have a great value for patient, their caregivers and for all of society. In the...
Funding Programme
Start Date
End Date
Total Funding
€ 1 100 000
European Countries Involved

Coordination Action in support of the implementation of a Joint Programming Initiative for Combating Neurodegenerative Diseases, in particular Alzheimer’s disease

JUMPAHEAD

The objective of the Coordination Action JUMPAHEAD is to support the implementation of the pilot Joint Programming Initiative on combating neurodegenerative diseases, in particular Alzheimer’s disease (JPND). Neurodegenerative disorders are incurable and debilitating conditions that result in progressive degeneration or death of nerve cells. Of...
Funding Programme
Start Date
End Date
Total Funding
€ 2 618 090

Critical solutions for elderly well-being

RISE-WELL

Mental health and emotional well-being during old age (60\) should be regarded as important as at any other time of a persons’ life. Older people are more likely to experience events that affect emotional well-being, such as bereavement or disability. Unfortunately, mental health problems are under identified in older people, whom themselves are...
Funding Programme
Start Date
End Date
Total Funding
€ 2 691 279
European Countries Involved

Integrative structural biology of pathological tau protein, an appealing therapeutic target for Alzheimer´s disease modifying drugs

InterTAU

There is an enormous and unmet medical need to find efficient methods of prevention, diagnosis and disease-modifying therapies for tauopathies, including Alzheimer’s disease. The common molecular denominator of tauopathies are pathological forms of tau protein. Tau pathology relates to conformational changes during oligomerization and assembly...
Funding Programme
Start Date
End Date
Total Funding
€ 1 062 600
European Countries Involved

NANOPARTICLES FOR THERAPY AND DIAGNOSIS OF ALZHEIMER DISEASE

NAD

The search for effective therapies and early detection strategies for Alzheimer’s Disease (AD), the major cause of dementia in Europe, is imperative. It is known that β-amyloid (Aβ) peptide plays a central role in neurodegeneration. In AD brain, Aβ is released in a soluble form that progressively becomes insoluble forming aggregates; extracellular...

Funding Programme
Start Date
End Date
Total Funding
€ 14 365 090

Pathway complexities of protein misfolding in neurodegenerative diseases: a novel approach to risk evaluation and model development

REfrAME

Neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementias and prion diseases affect ~50 million people worldwide. Alzheimer’s disease, the most prevalent form, affects ~6% of the population over 65 years of age and is one of the leading causes of death in the elderly. All these diseases have...
Funding Programme
Start Date
End Date
European Countries Involved

Synaptic Dysfunction in Alzheimer Disease

SyDAD

Given an overwhelming increase of dementia costs and an aging population, there is an urgent need for finding novel therapies for Alzheimer Disease (AD). We are, however, facing a large number of failed clinical trials and a retraction of the nervous system R&D programmes from several big pharmaceutical companies. Increased collaboration between...

Funding Programme
Start Date
End Date
Total Funding
€ 3 846 736
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).